AI-generated analysis. Always verify with the original filing.
BridgeBio Oncology Therapeutics, Inc. reported Q4 and full year 2025 financial results with net loss of $38.8 million and $134.0 million, respectively, alongside preliminary clinical data for BBO-8520, BBO-11818, and BBO-10203 showing encouraging safety and efficacy. Cash position of $425.5 million as of December 31, 2025, expected to fund operations into 2028.
Event Type
Disclosure
Mandatory
Variant
8-K
of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release dated March 5, 2026. 104 Cover Page Interactive Data File (embedded
| Metric | Value | Basis |
|---|---|---|
| Research and development expenses | $121.20 | GAAP |
| General and administrative expenses | $24.60 | GAAP |
| Net loss | $134.00 | GAAP |